ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV
Publication Type:
Journal Article
Authors:
Ferenci, P.;
Bernstein, D.;
Lalezari, J.;
Cohen, D.;
Luo, Y.;
Cooper, C.;
Tam, E.;
Marinho, R.T.;
Tsai, N.;
Nyberg, A.;
Box, T.D.;
Younes, Z.;
Enayati, P.;
Green, S.;
Baruch, Y.;
Bhandari, B.R.;
Caruntu, F.A.;
Sepe, T.;
Chulanov, V.;
Janczewska, E.;
Rizzardini, G.;
Gervain, J.;
Planas, R.;
Moreno, C.;
Hassanein, T.;
Xie, W.;
King, M.;
Podsadecki, T.;
K R Reddy;
PEARL-III study;
PEARL-IV studySource:
N Engl J Med, Volume 370, Issue 21, p.1983-1992 (2014)
Keywords:
Adult,
adverse effects,
Aged,
analysis,
Anilides,
Antiviral Agents,
blood,
Body Weight,
Carbamates,
clinical trial,
Drug Resistance,Viral,
drug therapy,
Drug Therapy,Combination,
Fatigue,
Female,
genetics,
Genotype,
genotype 1,
HCV,
Headache,
Hemoglobins,
Hepacivirus,
hepatitis,
Hepatitis C,
hepatitis C virus,
Hepatitis C,Chronic,
Humans,
Infection,
isolation & purification,
Macrocyclic Compounds,
Male,
methods,
Middle Aged,
Multicenter Studies,
Nausea,
Patients,
Recurrence,
Research,
Research Support,
Ribavirin,
ritonavir,
Rna,
Rna,Viral,
Safety,
sustained virologic response,
therapeutic use,
treatment,
virology
